Advances in α(v)β(3) integrin-targeting cancer therapy and imaging with radiolabeled RGD peptides

Current Radiopharmaceuticals

Volumn 2, Issue 3, 2009, Pages 214-219

  Mitrasinovic, Petar M ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Alpha(v)beta(3); Imaging; Integrin; RGD peptide; Therapy

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; HUMAN; ISOTOPE LABELING; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR;

EID: 77951121220     PISSN: 18744710     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874471010902030214     Document Type: Article

References (82)

1. Liu, S.; Robinson, S.P.; Edwards, D.S. Topics in Current Chemistry, Springer: Berlin-Heidelberg, 2005, pp. 193-216.
2. Kuijpers, B.H.M.; Groothuys, S.; Soede, A.C.; Laverman, P.; Boerman, O.C.; van Delft, F.L.; Rutjes, F.P.J.T. Preparation and evaluation of glycosylated arginine-glycine-aspartate (RGD) derivatives for integrin targeting. Bioconjug. Chem., 2007, 18, 1847-54.
3. Brooks, P.C. Role of integrins in angiogenesis. Eur. J. Cancer A, 1996,32, 2423-9.
4. Brooks, P.C.; Clark, R.A.; Cheresh, D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 1994, 264, 569-71.
5. Folkman, J. The role of angiogenesis in tumor growth. Semin. Cancer Biol., 1992, 3, 65-71.
6. Felding-Habermann, B.; O'Toole, T.E.; Smith, J.W.; Fransvea, E.; Ruggeri, Z.M.; Ginsberg, M.H.; Hughes, P.E.; Pampori, N.; Shattil, S.J.; Saven, A.; Mueller, B.M. Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA, 2001, 98, 1853-8.
7. Nip, J.; Shibata, H.; Loskutoff, D.J.; Cheresh, D.A.; Brodt, P. Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. J. Clin. Invest., 1992, 90, 1406-13.
8. Reinmuth, N.; Liu, W.; Ahmad, S.A.; Fan, F.; Stoeltzing, O.; Parikh, A.A.; Bucana, C.D.; Gallick, G.E.; Nickols, M.A.; Westlin, W.F.; Ellis, L.M. αvβ3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res., 2003, 63, 2079-83.
9. Meyer, A.; Auernheimer, J.; Modlinger, A.; Kessler, H. Targeting RGD recognizing integrins: Drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des., 2006, 12, 2723-47.
10. Allman, R.; Cowburn, P.; Mason, M. In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 integrin in human melanoma cells. Eur. J. Cancer, 2000, 36, 410-22.
11. Brooks, P.C.; Stromblad S.; Klemke, R.; Visscher, D.; Sarkar, F.H.; Cheresh, D.A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest., 1995,96, 1815-22.
12. Haubner, R. Alpha v beta 3-integrin imaging: a new approach to characterise angiogenesis? Eur. J. Nucl. Med. Mol. Imaging, 2006, 33(Suppl 1), 54-63.
13. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor vß3 integrin expression. J. Nucl. Med., 2007,48, 1162-71.
14. Janssen, M.; Oyen, W.J.; Massuger, L.F.; Frielink, C.; Dijkgraaf, I.; Edwards, D.S.; Radjopadhye, M.; Corstens, F.H.; Boerman, O.C. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother. Radiopharm., 2002, 17, 641-6.
15. Weissleder, R. Molecular imaging in cancer. Science, 2006, 312, 1168-71.
16. Haubner, R.H.; Wester, H.J.; Weber, W.A.; Schwaiger, M. Radiotracer-based strategies to image angiogenesis. Q. J. Nucl. Med., 2003, 47, 189-99.
17. Cai, W.; Gambhir, S.S.; Chen, X. Multimodality tumor imaging targeting integrin alpha v beta 3. BioTechniques, 2005, 39, S6-S17.
18. Yoshimoto, M.; Ogawa, K.; Washiyama, K.; Shikano, N.; Mori, H.; Amano, R.; Kawai, K. Alpha v beta 3 integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Int. J. Cancer, 2008, 123, 709-15.
19. Janssen, M.L.; Oyen, W.J.; Dijkgraaf, I.; Massuger, L.F.; Frielink, C.; Edwards, D.S.; Rajopadhye, M.; Boonstra, H.; Corstens, F.H.; Boerman, O.C. Tumor targeting with radiolabeled alpha v beta 3 integrin binding peptides in a nude mouse model. Cancer Res., 2002,62, 6146-51.
20. van Hagen, P.M.; Breeman, W.A.; Bernard, H.F.; Schaar, M.; Mooij, C.M.; Srinivasan, A.; Schmidt, M.A.; Krenning, E.P.; de Jong, M. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int. J. Cancer, 2000, 90, 186-98.
21. 64Cu-labeled RGD peptide. Bioconjug. Chem., 2004, 15, 41-9.
22. Singh, B.; Fu, C.; Bhattacharya, J. Vascular expression of the alpha v beta 3-integrin in lung and other organs. Am. J. Physiol. Lung Cell. Mol. Physiol., 2000, 278, L217-26.
23. Teitelbaum, S.L. Bone resorption by osteoclasts. Science, 2000, 289, 1504-8.
24. Grzesik, W.J.; Robey, P.G. Bone matrix RGD glycoproteins: immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J. Bone Miner. Res., 1994, 9, 487-96.
25. Hughes, D.E.; Salter, D.M.; Dedhar, S.; Simpson, R. Integrin expression in human bone. J. Bone Miner Res., 1993, 8, 527-33.
26. Dijkgraaf, I.; Kruijtzer, J.A.W.; Frielink, C.; Corstens, F.H.M.; Oyen, W.J.G.; Liskamp, R.M.J.; Boerman, O.C. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int. J. Cancer, 2006, 120, 605-10.
27. Schraa, A.J.; Kok, R.J.; Berendsen, A.D.; Moorlag, H.E.; Bos, E.J.; Meijer, D.K.F.; De Leij, L.F.M.H.; Molema, G. Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. J. Control Release, 2002, 83, 241-51.
28. 213Bi conjugated monoclonal antibody. Clin. Cancer Res., 2005, 11, 7070s-4s.
29. DeNardo, G.L.; Schlom, J.; Buchsbaum, D.J.; Meredith, R.F.; O'Donoghue, J.A.; Sgouros, G.; Humm, J.L.; DeNardo, S.J. Rationales, evidence, and design considerations for fractionated radio-immunotherapy. Cancer, 2002, 94, 1332-48.
30. 131I-labeled multivalent CC49 Single-chain Fvs. Clin. Cancer Res., 2001, 7, 175-84.
31. Anderson, C.J.; Jones, L.A.; Bass, L.A.; Sherman, E.L.; McCarthy, D.W.; Cutler, P.D.; Lanahan, M.V.; Cristel, M.E.; Lewis, J.S.; Schwarz, S.W. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J. Nucl. Med., 1998, 39, 1944-51.
32. Bombardieri, E.; Ferrari, L.; Spinelli, A.; Maffioli, L.; Seregni, E.; Braggi, G. Radioimmunotherapy of ovarian cancer with radiola-belled monoclonal antibodies: biological basis, present status and future perspectives. Anticancer Res., 1997, 17, 1719-29.
33. Epenetos, A.A.; Munro, A.J.; Stewart, S.; Rampling, R.; Lambert, H.E.; McKenzie, C.G.; Soutter, P.; Rahemtulla, A.; Hooker, G.; Sivolapenko, G.B. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled mono-clonal antibodies. J. Clin. Oncol., 1987, 5, 1890-99.
34. Nicholson, S.; Gooden, C.S.; Hird, V.; Maraveyas, A.; Mason, P.; Lambert, H.E.; Meares, C.F.; Epenetos, A.A. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis. Oncol. Rep., 1998,5, 223-6.
35. Rosenblum, M.G.; Verschraegen, C.F.; Murray, J.L.; Kudelka, A.P.; Gano, J.; Cheung, L.; Kavanagh, J.J. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharma-cokinetics and toxicity. Clin. Cancer Res., 1999, 5, 953-61.
36. 177Lu-CC49: a Phase I/II study. Gynecol. Oncol., 1997, 65, 94-101.
37. Meredith, R.F.; Alvarez, R.D.; Partridge, E.E.; Khazaeli, M.B.; Lin, C.Y.; Macey, D.J.; Austin, J.M. Jr.; Kilgore, L.C.; Grizzle, W.E.; Schlom, J.; LoBuglio, A.F. Intraperitoneal radioimmuno-chemotherapy of ovarian cancer: a phase I study. Cancer Biother. Radiopharm., 2001, 16, 305-15.
38. Alvarez, R.D.; Huh, W.K.; Khazaeli, M.B.; Meredith, R.F.; Partridge, E.E.; Kilgore, L.C.; Grizzle, W.E.; Shen, S.; Austin, J.M.; Barnes, M.N.; Carey, D.; Schlom, J. A phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res., 2002, 8, 2806-11.
39. Crippa, F.; Bolis, G.; Seregni, E.; Gavoni, N.; Scarfone, G.; Ferraris, C.; Buraggi, G.L.; Bombardieri, E. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur. J. Cancer, 1995, 31A, 686-90.
40. Zanten-Przybysz, I.; Molthoff, C.F.; Roos, J.C.; Plaizier, M.A.; Visser, G.W.; Pijpers, R.; Kenemans, P.; Verheijen, R.H. Radio-immunotherapy with intravenously administered I-131labelled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J. Nucl. Med., 2000, 41, 1168-76.
41. Colcher, D.; Esteban, J.; Carrasquillo, J.A.; Sugarbaker, P.; Reynolds, J.C.; Bryant, G.; Larson, S.M.; Schlom, J. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res., 1987, 47, 4218-24.
42. Koppe, M.J.; Bleichrodt, R.P.; Soede, A.C.; Verhofstad, A.A.; Goldenberg, D.M.; Oyen, W.J.G.; Boerman, O.C. Biodistribution and therapeutic efficacy of 125/131I-, 186Re-, 88/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J. Nucl. Med., 2004, 45, 1224-32.
43. Van Zanten-Przybysz, I.; Moltoff, C.F.; Roos, J.C.; Verheijen, R.H.; Van Hof, A.; Buist, M.R.; Prinssen, H.M.; Den Hollander, W.; Kenemans, P. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int. J. Cancer, 2001, 92, 106-14.
44. Griffin, T.M.; Collins, J.; Bokhari, F.; Stochl, M.; Brill, A.B.; Ito, T.; Emond, G.; Sands, H. Intraperitoneal immunoconjugates. Cancer Res., 1990, 50(Suppl), 1031S-8S.
45. Tibben, J.G.; Massuger, L.F.A.G.; Boerman, O.C.; Borm, G.F.; Claessens, R.A.M.J.; Corstens, F.H.M. Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3 F(ab')2 in experimental ovarian cancer. Eur. J. Nucl. Med., 1994, 21, 1183-90.
46. McDevitt, M.R.; Sgouros, G.; Finn, R.D.; Humm, J.L.; Jurcic, J.G.; Larson, S.M.; Scheinberg, D.A. Radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med., 1998, 25, 1341-51.
47. Norenberg, J.P.; Krenning, B.J.; Konings, I.R.; Kusewitt D.F.; Nayak, T.K.; Anderson, T.L.; de Jong, M.; Garmestani, K.; Brechbiel, M.W.; Kvols, L.K. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin. Cancer Res., 2006, 12, 897-903.
48. Washiyama, K.; Amano, R.; Sasaki, J.; Kinuya, S.; Tonami, N.; Shiokawa, Y.; Mitsugashira, T. 227Th-EDTMP: a potential therapeutic agent for bone metastasis. Nucl. Med. Biol., 2004, 31, 901-8.
49. O'Donoghue, J.A.; Bardies, M.; Wheldon, T.E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med., 1995, 36, 1902-9.
50. Cannistra, S.A.; Ottensmeier, C.; Niloff, J.; Orta, B.; DiCarlo, J. Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol. Oncol., 1995, 58, 216-25.
51. Albelda, S.M.; Mette, S.A.; Elder, D.E.; Stewart, R.; Damjanovich, L.; Herlynm M.; Buck, C.A. Integrin distribution in malignant melanoma: association of the 3 subunit with tumor progression. Cancer Res., 1990, 50, 6757-64.
52. Liapis, H.; Flath, A.; Kitazawa, S. Integrin 2\'P3 expression by bone-residing breast cancer metastases. Diagn. Mol. Pathol., 1996, 5, 127-35.
53. Zheng, D.Q.; Woodard, A.S.; Fornaro, M.; Tallini, G.; Languino, L.R. Prostatic carcinoma cell migration via alpha v beta 3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res., 1999,59, 1655-64.
54. Jin, H.; Varner, J. Integrins: roles in cancer development and as treatment targets. Br. J. Cancer, 2004, 90, 561-5.
55. Kumar, C.C. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug Targets, 2003, 4, 123-31.
56. Sipkins, D.A.; Cheresh, D.A.; Kazemi, M.R.; Nevin, L.M.; Bednarski, M.D.; Li, K.C. Detection of tumor angiogenesis in vivo by alpha v beta 3-targeted magnetic resonance imaging. Nat. Med., 1998,4, 623-6.
57. Ellegala, D.B.; Leong-Poi, H.; Carpenter, J.E. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation, 2003, 108, 336-41.
58. Chen, X.; Conti, P.S.; Moats, R.A. In vivo near-infrared fluorescence imaging of integrin alpha v beta 3 in brain tumor xenografts. Cancer Res., 2004, 64, 8009-14.
59. Haubner, R.; Wester, H.J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr. Pharm. Des., 2004, 10, 1439-55.
60. Liu, S.; Edwards, D.S.; Ziegler, M.C.; Harris, A.R.; Hemingway, S.J.; Barrett, J.A. 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug. Chem., 2001, 12, 624-9.
61. 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol., 2004, 6, 350-9.
62. 18F-labeled dimeric RGD peptide. Mol. Imaging, 2004, 3, 96-104.
63. Janssen, M.; Frielink, C.; Dijkgraaf, I. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother. Radiopharm., 2004, 19, 399-404.
64. 64Cu-labeled tetrameric RGD peptide. J. Nucl. Med., 2005, 46, 1707-18.
65. Sgouros, G. Dosimetry of internal emitters. J. Nucl. Med., 2005, 46(Suppl), 18S-27S.
66. International Commission on Radiological Protection. Recommendation of the Internetional Commission on Radiation Protection. ICRP Publication. Ann ICRP, Pergamon Press. Oxford, 1991, 21(1-3).
67. Anderson, C.J.; Dehdashti, F.; Cutler, P.D. Copper-64-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med., 2001, 42, 213-21.
68. Jamar, F.; Barone, R.; Mathieu, I. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 510-8.
69. Bello, L.; Francolini, M.; Marthyn, P. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery, 2001,49, 380-9.
70. Chen, X.; Park, R.; Shahinian, A.H.; Bading, J.R.; Conti, P.S. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol., 2004, 31, 11-9.
71. Chen, X.; Park, R.; Shahinian, A.H. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl. Med. Biol., 2004, 31, 179-89.
72. Chen, X.; Hou, Y.; Tohme, M. PEGylated RGD peptide: 64Cu-labeling and PET imaging of brain tumor angiogenesis. J. Nucl. Med., 2004, 45, 1776-83.
73. Boturyn, D.; Coll, J.-L.; Garanger, E.; Favrot, M.-C.; Dumy, P. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J. Am. Chem. Soc., 2004, 126, 5730-9.
74. Garanger, E.; Boturyn, D.; Coll, J.L.; Favrot, M.C.; Dumy, P. Multivalent RGD synthetic peptides as potent alpha v beta 3 integrin ligands. Org. Biomol. Chem., 2006, 4, 1958-65.
75. Garanger, E.; Boturyn, D.; Jin, Z.; Dumy, P.; Favrot, M.C.; Coll, J.L. New multifunctional molecular conjugate vector for targeting, imaging and therapy of tumors. Mol. Ther., 2005, 12, 1168-75.
76. Castel, S.; Pagan, R.; Mitjans, F.; Piulats, J.; Goodman, S.; Jonczyk, A.; Huber, F.; Vilaro, S.; Reina, M. RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways. Lab. Invest., 2001, 81, 1615-26.
77. Schraa, A.J.; Kok, R.J.; Berendsen, A.D.; Moorlag, H.E.; Bos, E.J.; Meijer, D.K.; de Leij, L.F.; Molema, G. Targeting of RGD-modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study. Int. J. Cancer, 2002, 102, 469-75.
78. Garanger, E.; Boturyn, D.; Renaudet, O.; Defrancq, E.; Dumy, P. Chemoselectively addressable template: a valuable tool for the engineering of molecular conjugates. J. Org. Chem., 2006, 71, 2402-10.
79. Razkin, J.; Josserand, V.; Boturyn, D.; Jin, Z.; Dumy, P.; Favrot, M.; Coll, J.-L.; Texier, I. Activatable fluorescent probes for tumour-targeting imaging in live mice. Chem. Med. Chem., 2006, 1, 1069-72.
80. Jin, Z.; Josserand, V.; Razkin, J.; Garanger, E.; Boturyn, D.; Favrot, M.-C.; Dumy, P.; Coll, J.-L. Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4. Mol. Imaging, 2006, 5, 188-97.
81. Montet, X.; Funovics, M.; Montet-Abou, K.; Weissleder, R.; Josephson, L. Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem., 2006, 49, 6087-93.
82. Garanger, E.; Boturyn, D.; Dumy, P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anti-Cancer Agents Med. Chem., 2007, 7, 552-8.